Efficacy of basiliximab in the treatment of 87 cases of steroid-refractory or steroid-dependent acute graft-versus-host disease  

作　　者：HE Zhenxin 贺振新(State Key Experiment Hematol Lab,Natl Clin Blood Dis Res Center,Instit Hematol&Blood Dis Hosp,CAMS&PUML,Tianjin 300020)

机构地区：[1]State Key Experiment Hematol Lab,Natl Clin Blood Dis Res Center,Instit Hematol&Blood Dis Hosp,CAMS&PUML,Tianjin 300020

出　　处：《China Medical Abstracts(Internal Medicine)》2022年第2期121-122,共2页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To evaluate the efficacy and prognosis of basiliximab in the treatment of steroid-refractory or steroid-dependent acute graft-versus-host disease (SR/SDaGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).Methods Clinical data of 87patients with SR/SD-aGVHD in the skin, intestine, and liver after allo-HSCT at the Institute of Hematology&Blood Diseases Hospital Transplantation Center from January 2015 to December 2018 were retrospectively analyzed.

关 键 词：BLOOD INTESTINE ACUTE 

分 类 号：R457.7[医药卫生—治疗学]